Results 201 to 210 of about 111,280 (248)

Contrasting mechanisms for crustal sulphur contamination of mafic magma: evidence from dyke and sill complexes from the British Palaeogene Igneous Province

open access: gold, 2016
Hannah S.R. Hughes   +6 more
openalex   +1 more source

A black macule on the male nipple. [PDF]

open access: yesJAAD Case Rep
Fujii N   +3 more
europepmc   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg   +2 more
wiley   +1 more source

Volcanic forcing of the Lomagundi-Jatuli carbon isotope excursion. [PDF]

open access: yesProc Natl Acad Sci U S A
Blichert-Toft J   +6 more
europepmc   +1 more source

Eczema Monkeypoxicum Following Sexual Transmission Treated With Tecovirimat

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Mpox is a zoonotic viral infection caused by monkeypox virus (MPXV) and risk factors for its dissemination include previous dermatoses such as atopic dermatitis [1]. We present the case of a 30‐year‐old male with an unusual and extensive presentation of mpox following unprotected sexual intercourse, with an excellent response to tecovirimat ...
Andrés Vidal González   +6 more
wiley   +1 more source

Exo-Geoscience Perspectives Beyond Habitability. [PDF]

open access: yesSpace Sci Rev
Spohn T   +7 more
europepmc   +1 more source

Dupilumab Treatment in Pemphigus: A Report of Three Cases and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pemphigus vulgaris (PV) and foliaceus (PF) are rare autoimmune blistering diseases traditionally treated with systemic corticosteroids, immunosuppressants, intravenous immunoglobulins, and rituximab. Nonetheless, a subset of patients remains refractory or has contraindications to these conventional therapies.
José Javier Mateos Rico   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy